Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
| العنوان: | Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist |
|---|---|
| المؤلفون: | Jon Trærup Andersen, Filip K. Knop, Signe Vinsand Naver, Mikkel Christensen, Espen Jimenez-Solem |
| المصدر: | Clinical Investigation. 4:729-743 |
| بيانات النشر: | OMICS Publishing Group, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Agonist, medicine.medical_specialty, business.industry, medicine.drug_class, Nausea, General Medicine, Type 2 diabetes, Pharmacology, Hypoglycemia, medicine.disease, Endocrinology, Internal medicine, Medicine, Dulaglutide, medicine.symptom, Adverse effect, business, Receptor, Glucagon-like peptide 1 receptor, medicine.drug |
| الوصف: | Dulaglutide is a novel continuous-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of Type 2 diabetes. It consists of two modified ‘GLP-1’ moieties covalently linked to a human immunoglobulin (IgG) 4-FC heavy chain. The large size of the molecule prolongs plasma half-life and allows for once-weekly administration. Clinical Phase II and III trials show dose-dependent reductions of HbA1c up to 1.6%, reduction in fasting plasma glucose up to 2.7 mmol/l and weight reductions up to 3.2 kg. Presumably, a dose of 1.5 mg once weekly will be the intended dose for treatment. Safety data indicate a low incidence of hypoglycemia and the most frequently reported adverse events are gastrointestinal, primarily nausea, which seem to reduce over time. |
| تدمد: | 2041-6806 2041-6792 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::7c1ec59c4caa105fe68073b319b44868Test https://doi.org/10.4155/cli.14.65Test |
| رقم الانضمام: | edsair.doi...........7c1ec59c4caa105fe68073b319b44868 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20416806 20416792 |
|---|